No Data
Ultragenyx Posts Trial Data Backing Phase 3 Design for Angelman Syndrome Therapy
Express News | Ultragenyx Presents Positive Update on Gtx-102 Angelman Syndrome Program at Fast’s 17TH Annual Global Science Summit
Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST's 17th Annual Global Science Summit
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
A Quick Look at Today's Ratings for Ultragenyx Pharmaceutical(RARE.US), With a Forecast Between $70 to $135
Analysts Conflicted on These Healthcare Names: Ultragenyx Pharmaceutical (RARE), Henry Schein (HSIC) and McKesson (MCK)
No Data
No Data